CONCLUSIONS
This study further confirms the safety of COVID-19 vaccination in the neuroimmune disease population, especially those with autoimmune neurological conditions. Stable patients with neuroimmune disorders should be encouraged to receive COVID-19 vaccination. Further research should monitor for serious adverse events following vaccination and the long-term impact of vaccination on patients with neuroimmune diseases.
Abbreviations: ANC:autoimmune neurological conditions; SARS-CoV-2 :severe acute respiratory syndrome type 2 coronavirus; MS: multiple sclerosis; MG: myasthenia gravis; NMOSD: neuromyelitis optica spectrum disorder; GBS: Guillain-Barre syndrome; CIDP: chronic inflammatory demyelinating polyneuropathy; IST: immunosuppressive therapy; MMN: multifocal motor neuropathy